Sigma Healthcare (SIG) Trading Update summary

Trading performance and EBIT growth

• Normalised EBIT for the nine months to 31 March 2025 grew in line with Chemist Warehouse Group's (CWG) 36% growth for 1H FY25 versus 1H FY24.

• Normalised EBIT excludes merger-related transaction costs and purchase price allocation impacts.

• Transaction costs totaled $42.4m to 31 March 2025, with $8.1m in 1H FY25 and $34.3m in Q3 FY25.

Merger and financial reporting

• Sigma completed its merger with CWG on 12 February 2025, with CWG treated as the accounting acquirer.

• FY25 consolidated results will include 12 months of CWG and Sigma from the merger date; pre-merger Sigma transaction costs are excluded from FY25 consolidated financials.

Future reporting and statutory results

• Sigma will release statutory results for the twelve months ending 30 June 2025 in August 2025.

• CWG's 1H FY25 results, reported before the merger, do not include Sigma's contribution.

• Some CWG earnings from sales to Sigma pre-merger will be eliminated as inter-company sales post-merger.